Its 39-residue sequence is engineered around a GIP backbone rather than the more commonly modified GLP-1 scaffold, a design choice that fundamentally shapes its receptor pharmacology and distinguishes it from earlier dual-agonist candidates that simply chained GLP-1 and glucagon sequences together
adults who tolerate it for at least four weeks may increase to a maximum 7.2 mg when additional weight reduction is clinically indicated
Key drivers behind GLP-1 and addiction research include: Rapid expansion in the use of GLP-1 medications such as semaglutide (Ozempic and Wegovy) and tirzepatide (Maunjaro and Zepbound) Reports of changes in cravings, alcohol use, or reward-seeking behaviors beyond weight loss Increased public conversation and clinical curiosity about psychological and behavioral effects Scientific interest in GLP-1 activity within reward pathways and dopamine signaling Recognition that appetite regulation and addiction involve shared neural mechanisms This research is still emerging, and findings should be interpreted with caution
The patch includes natural botanicals such as white peony root, cinnamon, ginger, wormwood, cardamom, tangerine peel, clove, pepper seed, astragalus, and licorice
